Modulation of Toll-Like Receptor Signalling as a New Therapeutic Principle
2010
Modulating Immune Responses for Better Treatments
Editorial
Author Information
Author(s): Philipp M. Lepper, Martha Triantafilou, Luke A. O'Neill, Natalija Novak, Hermann Wagner, Andrew E. Parker, Kathy Triantafilou
Hypothesis
Can targeting Toll-Like Receptor signaling improve therapeutic interventions for inflammatory disorders?
Conclusion
Targeting Toll-Like Receptors may lead to more specific and effective treatments for various inflammatory diseases.
Supporting Evidence
- Toll-Like Receptors are involved in various diseases including cancer and autoimmune disorders.
- Research shows that TLRs can initiate and propagate inflammation.
- Targeting TLR pathways may lead to more specific treatments for inflammatory disorders.
Takeaway
Scientists are looking at special parts of our immune system to help make better medicines for sicknesses like allergies and infections.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website